Project Details
Description
A phase III clinical trial to study the tolerability and immunogenicity of a multivalent human papillomavirus (HPV) L1 virus-like particle (BLP) vaccine in men 16 to 26 years of age and women 16 to 26 years of age.
The purpose of this study is to evaluate the efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine (9vHPV) against human papillomavirus in men and women aged 16 to 26 years.
The purpose of this study is to evaluate the efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine (9vHPV) against human papillomavirus in men and women aged 16 to 26 years.
| Status | Finished |
|---|---|
| Effective start/end date | 4/1/13 → 4/1/14 |
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
Main Funding Source
- Installed Capacity (Academic Unit)
Location
- South America